{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0372","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.08","upperLimit":"18.17","value":"16.13"},{"groupId":"OG001","lowerLimit":"14.36","upperLimit":"21.29","value":"17.28"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"218"},{"groupId":"OG001","value":"222"}],"units":"Participants"}],"description":"Overall survival was defined as time from the day of randomization to death for patients died. For patients still alive at time of data-cutoff for analysis, it was censored at the last day the patients were known alive as the last of all dates .","dispersionType":"95% Confidence Interval","groups":[{"description":"Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles\n\nCisplatin\n\nPemetrexed","id":"OG000","title":"Arm A - Cisplatin/Pemetrexed"},{"description":"Pembrolizumab 200 mg\\* IV Day 1 over 30 min every 21 days for a total of 2 years Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles\n\nCisplatin\n\nPemetrexed\n\nPembrolizumab","id":"OG001","title":"Arm B - Cisplatin/Pemetrexed/Pembrolizumab"}],"paramType":"MEDIAN","populationDescription":"Intention to treat population.","reportingStatus":"POSTED","timeFrame":"Survival was monitored continuously throughout the study and during follow-up. Patients were evaluated for each cycle, 4 weeks after discontinuation, every 12 weeks until progression, and then every 24 weeks until death, an average of 16.2 months.","title":"Phase III: Overall Survival Defined as Time From Randomization to the Date of Death From Any Cause","type":"PRIMARY","unitOfMeasure":"months"}